Stay updated on CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial
Sign up to get notified when there's something new on the CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial page.

Latest updates to the CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoChange DetectedAdded a Locations section with study sites in Indiana, New York, and Ohio; updated the page revision to v3.3.3.SummaryDifference0.4%

- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedThe only observed change is the revision label updating from v3.3.1 to v3.3.2, with no substantive changes to content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check38 days agoChange DetectedRevision label updated from v3.2.0 to v3.3.1; there are no visible changes to the study information or page design.SummaryDifference0.0%

- Check45 days agoChange DetectedStudy status updated to Active, not recruiting with enrollment at 51, and update timestamps added/updated to reflect current activity.SummaryDifference0.8%

- Check59 days agoChange DetectedSubstantive study information (objectives, outcomes, inclusion/exclusion criteria, and locations) remains unchanged. The observed changes appear to be minor formatting or metadata updates to the page content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check89 days agoChange DetectedSummary: The page updates to version v3.2.0 and removes a specific resource titled “Head and neck squamous cell carcinoma.” This indicates a pruning of a resource reference while introducing a new version. If there are no other content changes, then this is a minor to moderate update.SummaryDifference0.3%

Stay in the know with updates to CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial page.